Pfizer said it will partner with Keas, a developer of online health organizers, to “enable health and wellness experts to author, sell and distribute personalized online care plans directly to patients.”
Social media marketers should make it easy for consumers to consider the source when products are being discussed, according to new disclosure guidelines from the Word of Mouth Marketing Association (WOMMA).
Vantage Point: new era of marketing research
February 15, 2010
4:02 pm
For years, healthcare marketing research has begun with a proposal and ended with a final report containing “conclusions” and “recommendations.”
Corporate officials are ‘responsible’
February 15, 2010
10:28 pm
In an adverse finding on an appeal by Purdue Pharma executives over OxyContin marketing, an HHS Departmental Appeals Board says that corporate officials can be held responsible for their organization’s legal problems, even if they weren’t personally aware they were occurring.
Obama’s second budget for FDA sets another record
February 15, 2010
10:27 pm
A week after promising non-military government austerity in his State of the Union address, President Obama proposes a second successive record annual hike in FDA funding—up 23% on top of his 19% boost last year—to include new product safety programs and user fees.
Social media continues to be something of a blind spot for the pharma and medical device industries, with only a tiny fraction of all marketing dollars spent on online marketing.
Dropped call: the digital story everyone’s missing
Funny what gets people’s attention. Today’s topic du jour is social media—every pharma company sports an ad hoc committee, umpteen hyperbolic stories in the press, heck even the FDA has taken notice!
Tackling the journal advertising challenge
February 15, 2010
10:07 pm
Integrating journal ads into a media schedule was a challenge before professional media entered a period of contraction. With ad budgets shrinking and use of new channels growing, what are the keys to integration?
It was activism that drew the world’s attention to the HIV epidemic and to the need for ethical standards in AIDS-drug testing. And activism is once again playing a role, this time in challenging a drug company, Merck, over the price of HIV/AIDS medicine Isentress.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix